In a startling break with tradition, the American College of Cardiology and the Society of Thoracic Surgeons will manage and run their own clinical trials testing expanded uses for transcatheter aortic valve replacement (TAVR).
Valve's Joe Ludwig says that the TF2's robust community is ideal for testing out the new technology, and both companies are eager to see how the community reacts.